The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
that drug was extremely important for all the signs because that drug only raised HDL it was a very weak CTP inhibitor it only raised HDL by 30 percent and there was no effect on the koplamaya curve in the cardiovascular outcome style whatsoever and what people didn't realize that drug was the end of the HDL hypothesis
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.